All In Biotech

Drug Trial Radar · NCT06579144

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

An Open-label, Multicentre Study to Compare the Pharmacokinetics of Efanesoctocog Alfa Versus rFVIII Products, Damactocog Alfa Pegol or Turoctocog Alfa Pegol, After a Single Intravenous Dose of 50 IU/kg in a Fixed Sequence in Previously Treated Adults With Severe Haemophilia A.

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Feb 24, 2025

Primary completion

May 21, 2026

Study completion May 21, 2026

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
Collaborators
PSI CRO
First posted
Aug 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Sobi.BIVV001-003 is an open-label, 2-period, fixed sequence study for intra-participant comparison of the PK profiles of efanesoctocog alfa and the extended half-life rFVIII products damactocog alfa pegol or turoctocog alfa pegol after a single i.v. injection in previously treated males, 18-65 years of age, with severe haemophilia A. Participants who are receiving treatment with damoctocog alfa pegol (n\~12) or turoctocog alfa pegol (n\~12) will be enrolled in the study. The study will start with a screening period (up to 28 days), including a wash-out period prior to start of the actual study period. During the the first visit, a single dose of damactocog alfa pegol or turoctocog alfa pegol (corresponding to the participant's pre-study treatment) will be administered. A PK sampling period will follow over 7 visits. Following completion of the PK sampling of the original treatment regimen, the patients will be given a single dose of efanesoctocog alfa at visit 8, after which a new PK sampling period will follow (visit 8-15). The primary objective for the study is to compare the half-life of efanesoctocog alfa with that of the two comparator drugs after a single iv. injections. Secondary objectives include comparison of area under the curve for efanesoctocog alfa vs. the two comparator drugs, characterization of PK parameters for all three drugs as well as well as to evaluate safety and tolerability of a single iv. injection of efanesoctocog alfa.

Conditions

  • Hemophilia A

Interventions

  • Efanesoctocog alfaDrug

    Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Half-life (t½) of efanesoctocog alfa, damactocog alfa pegol and turoctocog alfa pegol after a single i.v. injectionTime frame: up to 7 days and 14 days after the administration of the respective drugs.

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Sobi Investigational Site

    Sofia, Bulgaria

  • Sobi Investigational Site

    Bonn, Germany

  • Sobi Investigational site

    Frankfurt, Germany

  • Sobi Investigational Site

    Milan, Italy

  • Sobi Investigational Site

    A Coruña, Spain

  • Sobi Investigational Site

    Valencia, Spain

  • Sobi Investigational Site

    Zaragoza, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.